Gene

PTEN

phosphatase and tensin homolog

Explore in graph →CI-GENE-00022414HGNC:9588 ENSG00000171862 NCBI 5728 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (136)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 136 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600 + PTEN UnderexpressionBRAF PTEN1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Brain Lower Grade Glioma (TCGA, PanCancer Atlas) lgg_tcga_pan_can_atlas_2018	Diffuse Glioma

Literature

Linked publications (53)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 53 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
· N Engl J Med · 2023 · PMID 37256976 · validated civic_curation pubmed
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.
· Br J Cancer · 2007 · PMID 17700571 · validated civic_curation pubmed
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
· Br J Cancer · 2013 · PMID 23989949 · validated civic_curation pubmed
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
· N Engl J Med · 2005 · PMID 16282176 · validated civic_curation

BRAF V600E + PTEN LossBRAF PTEN2
Uprosertib	Melanoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID708 Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
Dabrafenib + UprosertibCombination	Melanoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID13116 Several BRAF V600E mutant melanoma cell lines (M249, M399, M397AR)) with PTEN mutation or loss of expression were among those sensitive to combination dabrafenib plus AKT inhibitor GSK2141795B, as mea… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic

PIK3CA K111N + PTEN UnderexpressionPIK3CA PTEN7
Dactolisib	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Resistance	2	accepted	EID8276 In a preclinical study, efficacy of dactolisib monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN exp… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
Dactolisib + TrastuzumabCombination	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID8283 In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induced PTEN expr… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
Lapatinib	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Resistance	4	accepted	EID8275 In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN ex… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
Dactolisib + LapatinibCombination	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID8278 In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and lapatinib combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (h… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
Lapatinib + TrastuzumabCombination	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID8277 In a preclinical study, efficacy of lapatinib and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induced PTEN expression loss. A… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
Trastuzumab	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Resistance	2	accepted	EID8274 In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN ex… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic
Dactolisib + TrastuzumabCombination	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID8279 In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified human breast cancer cell line … (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC	civic

PTEN Deletion4
(prognostic)	Prostate Adenocarcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID505 In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those witho… (full text at CIViC) PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Prognostic	B	Supports Poor Outcome	4	rejected	EID643 PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer. PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Prognostic	B	Supports Poor Outcome	4	accepted	EID1741 A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason s… (full text at CIViC) PMID 27470558 · Gao et al., 2016 · Open in CIViC	civic
Everolimus	Malignant Prostate Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID1231 In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p… (full text at CIViC) PMID 23582881 · Templeton et al., 2013 · Open in CIViC	civic

PTEN Expression5
Dacomitinib	GlioblastomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	accepted	EID775 In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII… (full text at CIViC) PMID 25939761 · Zahonero et al., 2015 · Open in CIViC	civic
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID774 49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic
Erlotinib + GefitinibSubstitutes	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1129 Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment w… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC	civic
Everolimus + FulvestrantCombination	HER2-Positive Breast CarcinomaALIAS	Predictive	C	Supports Resistance	1	accepted	EID1624 Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classica… (full text at CIViC) PMID 27445490 · Sun et al., 2016 · Open in CIViC	civic
Trastuzumab	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID955 Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC). PMID 16404430 · Fujita et al., 2006 · Open in CIViC	civic